Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Sets Generic Mucinex Launch After Patent Claim Decision

This article was originally published in The Tan Sheet

Executive Summary

The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.

Advertisement

Related Content

Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate
Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
Sales & Earnings In Brief
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Sales & Earnings In Brief
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel